The clinical guideline for CG76 Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence has been checked by NICE for the need for update.
Registered stakeholders for the guideline are invited to comment on the provisional decision via this website. Please see the consultation page for more details.
Review decision date: March 2015
Next review date: March 2017
This guidance is about enabling patients to make informed choices by involving and supporting them in decisions about prescribed medicines. It explains guidance (advice) from NICE (the National Institute for Health and Clinical Excellence) to the NHS in England and Wales.
Responsibility for undertaking a review of this guidance at the designated review date has passed to the National Clinical Guidelines Centre for Acute and Chronic Conditions (NCGCACC). The National Collaborating Centre for Primary Care is no longer active.
March 2015: Recommendation 1.4.2 has been replaced by recommendations in the NICE guideline on medicines optimisation.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.